Human Oncology & Pathogenesis Program

The Sarat Chandarlapaty Lab

Research

Sarat Chandarlapaty, MD, PhD

My lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis.

View Lab Overview

Featured News

In the Lab

Researchers Identify Mutations that Cause Some Breast Cancers to Resist Treatment

Friday, November 8, 2013

In the Clinic

Liquid Biopsy Shown to Be Effective in Assessing Response to Breast Cancer Drugs

Friday, December 11, 2015

Publications

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. (2020). Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer, Mar;1(4):382–393.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. (2018). Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, Dec;34(6):893-905.

Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S*, Rosen N.* (2014). Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov, Mar;4(3):334-47.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. (2013). ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet, Dec;45(12):1439-45.

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder P.K, Baselga J, Rosen N. (2011). AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell, Jan;19(1):58-71.

View All Publications

People

Sarat Chandarlapaty, MD, PhD

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
MD, Wake Forest School of Medicine
PhD, University of North Carolina

[email protected]: Email Address
View physician profile: Physician profile

Members

Yanyan Cai

Bo Liu, Research Associate — Bo Liu
Research Associate

Payal Patel

Graduate Student

Ramya Segu Rajappachetty
Research Technician Sr.

Hong Shao

Lab Alumni

ChengCheng Yang
Graduate Research Assistant

Lab Affiliations

Achievements

Clinical Investigator Award, Damon Runyon Cancer Research Foundation (2012)
Young Investigator Award, American Society of Clinical Oncology (2007)
Fellow in Biomedical Research, The Dana Foundation (2006)

Open Positions

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

Breast Cancer Research Foundation
Provision of Services
Eli Lilly and Company
Provision of Services
Global Breast Cancer Conference
Provision of Services (uncompensated)
National Comprehensive Cancer Network
Provision of Services

Novartis
Provision of Services
Paige.AI, Inc.
Provision of Services
Sanofi US Services Inc.
Provision of Services
Seoul Breast Cancer Symposium
Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures